Invention Application
US20120096571A1 EGLN2 VARIANTS AND USE THEREOF IN PREVENTING OR TREATING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASES
失效
EGLN2变异体及其在预防或治疗血栓性疾病和冠状动脉疾病中的应用
- Patent Title: EGLN2 VARIANTS AND USE THEREOF IN PREVENTING OR TREATING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASES
- Patent Title (中): EGLN2变异体及其在预防或治疗血栓性疾病和冠状动脉疾病中的应用
-
Application No.: US13331581Application Date: 2011-12-20
-
Publication No.: US20120096571A1Publication Date: 2012-04-19
- Inventor: Detlef KOZIAN , Matthias HERRMANN
- Applicant: Detlef KOZIAN , Matthias HERRMANN
- Applicant Address: FR Paris
- Assignee: SANOFI
- Current Assignee: SANOFI
- Current Assignee Address: FR Paris
- Priority: DE102005048898.6 20051012
- Main IPC: C12P21/02
- IPC: C12P21/02 ; C12N15/63 ; C12N1/19 ; C12N5/10 ; C12N1/21 ; C12N15/12 ; A01K67/027
Abstract:
The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.
Public/Granted literature
Information query
